Although guidelines for vitamin D supplementation in infants have been widely implemented, they are mostly based on studies focusing on prevention of rickets. The optimal dose for bone strength and infection prevention in healthy infants remains unclear.
F or decades, vitamin D deficiency has been a worldwide health concern.
1 Many countries have implemented guidelines for vitamin D supplementation and food fortification, but preventive measures have not been adequate. 2 In the United States, vitamin D deficiency, defined as serum 25-hydroxyvitamin D (25[OH]D) concentration less than 20.03 ng/mL (to convert to nanomoles per liter, multiply by 2.496), was reported in 1988 to 2010 in 26% to 32% of the population. 3 Likewise, a 2016 study involving more than 50 000 European adults and children estimated 40% to be vitamin D deficient. 4 Vitamin D deficiency in infants can lead to impaired bone mineralization and rickets. 5 Since the 1920s, vitamin D has been recognized as effective in preventing and treating rickets, but optimal supplementation for bone health is still unclear, with data on the skeletal effects of vitamin D in infants being scarce. [6] [7] [8] Vitamin D is a potent modulator of both innate and adaptive immunity. 9 Some observational studies report an association between vitamin D deficiency and increased infectious diseases. [10] [11] [12] Randomized trials, however, show conflicting results and few involve infants. [13] [14] [15] Because infections are a major cause of early childhood morbidity, the effect of vitamin D supplementation is of great interest. We conducted a randomized clinical trial comparing daily vitamin D 3 supplementation of 400 IU and 1200 IU in healthy infants aged 2 weeks to 24 months. Our aim was to evaluate effects of vitamin D supplementation on bone strength and incidence of infections. We hypothesized that higher dosages of vitamin D supplementation would lead to increased bone strength and to decreased frequency of infections in early childhood.
Methods

Study Design and Participants
The Vitamin D Intervention in Infants (VIDI) study was a randomized, double-blind, 24-month clinical trial of daily vitamin D 3 supplementation of 400 IU or 1200 IU administered to infants. Between January 14, 2013, and June 9, 2014, families were recruited at Kätilöopisto Helsinki Maternity Hospital, Helsinki, Finland, 1 to 2 days after delivery. All follow-up was completed on May 30, 2016. Mothers took no regular medication and had a singleton pregnancy. Ethnicity was restricted to Northern European to exclude the effect of skin pigmentation on vitamin D status. 16 Eligible infants were born at term (37 weeks and 0 days' to 42 weeks and 0 days' gestation), with a birth weight within 2 SDs of the mean for gestational age. 17 Infants excluded were those requiring intravenous glucose, antibiotics, nasal continuous positive airway pressure treatment for more than 1 day, phototherapy for more than 3 days, or nasogastric tube feeding for more than 1 day and infants with seizures.
The study was conducted in accordance with the Declaration of Helsinki, and the Research Ethics Committee of the Hospital District of Helsinki and Uusimaa approved the study.
The project protocol is provided in Supplement 1 and has been described in a previously published article. 18 Parents gave written informed consent at recruitment.
Randomization and Blinding
Infants were randomized (1:1) to receive 400 IU or 1200 IU of vitamin D 3 daily from age 2 weeks to 24 months. To ensure fair distribution across the year, a pharmacist at Helsinki University Hospital with no relation to the study performed randomization in blocks of 50. Both study preparations, manufactured by Orion Pharmaceuticals, contained vitamin D 3 dissolved in medium-chain triglyceride oil and were identical in appearance. Participants and investigators were masked to group assignment, and no changes to the methods were made after trial commencement. An external steering group monitored the study.
Procedures
Vitamin D supplements were administered orally once daily in a volume of 5 drops for both concentrations. No other vitamin D supplements were allowed concurrently. The families recorded daily vitamin D supplementation and all their child's infections in study diaries. Completed diaries were collected and reviewed at follow-up visits arranged at ages 6, 12, and 24 months. Adherence to treatment was calculated from the diaries as the percentage of days of supplement administration compared with the total number of days of follow-up. We analyzed 25(OH)D concentration (in nanograms per milliliter; to convert to nanomoles per liter, multiply by 2.496) at birth (cord blood) and at ages 12 and 24 months and intact parathyroid hormone concentration at ages 12 and 24 months with a fully automated immunoassay (IDS-iSYS; Immunodiagnostic System Ltd). Details on data collection and laboratory analyses are provided in eAppendix 1 and eAppendix 2 in Supplement 2.
Outcome Measures
The primary outcomes were bone strength and incidence of parent-reported infections at 24 months. We used 4 different bone measurements for total and cortical bone to assess bone strength because none of these alone determines fracture resistance. 19 Bone mineral content reflects bone mineral quantity (in milligrams) per millimeter, bone mineral density reflects bone mineral quantity (in milligrams) per cubic centi-
Key Points
Question Does a higher dose (1200 IU) of supplemental vitamin D 3 administered to healthy infants increase bone strength or decrease incidence of infections compared with the standard dose (400 IU)?
Findings This randomized clinical trial of 975 infants found no difference in bone strength or incidence of infections between intervention groups at 24 months of age.
Meaning In healthy infants, daily supplementation with 1200 IU of vitamin D 3 provides no additional benefits compared with supplementation with 400 IU for bone strength or incidence of infections in early childhood.
meter, cross-sectional area of the bone reflects bone area in square millimeters, and polar moment of inertia reflects bone resistance to torsion (measured in quartic millimeters). These bone strength measurements were assessed at age 24 months with peripheral quantitative computed tomography (pQCT) (Stratec XCT 2000 L Research+; Stratec Medizintechnik GmbH) of the left tibia. The length of the tibia was measured from the medial malleolus to the medial condyle, and bone strength was measured at 20% distal proximal length. We graded each pQCT scan quality according to movement artifacts from 1 to 5 and further as good (grades 1-2), moderate (grades 3-4), or poor (grade 5). 20 If major movement artifacts or incorrect leg positioning occurred, the scan was excluded. Infections were assessed from study diaries in which parents prospectively recorded all their child's infections. Parents reported the date of the infection (month/year), infection type, symptoms or specific diagnosis, duration, medication, physician visit, or hospitalization. The cumulative number of infection episodes was calculated for the 24-month study. If several symptoms or diagnosed infections were reported for the same period, these were considered as belonging to the same episode.
For characterization, the parent-reported infections were divided post hoc into 7 subtypes: (1) upper respiratory tract infection, defined as presence of rhinitis, cough, sore throat, nasal congestion, or sneezing, with or without fever (temperature, >38.0°C); (2) acute otitis media diagnosed by a physician; (3) pneumonia diagnosed by a physician; (4) conjunctivitis, defined as reddish eye, discharge from the eye, or both; (5) gastroenteritis, defined as vomiting and/or diarrhea; (6) nonspecified viral infection, defined as fever (temperature, >38.0°C) with or without skin manifestations; and (7) other bacterial infection including miscellaneous bacterial infections, such as of the urinary tract or skin. For outcome analyses, the infections were further grouped into 3 main types: (1) respiratory infections, including upper respiratory tract infections, acute otitis media, and pneumonia; (2) gastroenteritis; and (3) other bacterial and viral infections, including conjunctivitis.
Safety Monitoring
Trial safety was ensured by measurement of the ionized calcium concentration at follow-up visits. In case of severe hypercalcemia, defined as an ionized calcium concentration exceeding the upper age-specific reference limit by 10% or more (ie, 6.12 mg/dL at ages 6 and 12 months and 5.92 mg/dL at age 24 months; to convert to millimoles per liter, multiply by 0.25), calcium and 25(OH)D concentrations were to be remeasured, symptoms indicative of hypercalcemia investigated, and continuation of vitamin D supplementation reevaluated. In case of any adverse effects or severe hypercalcemia, an external monitor was to be informed.
Statistical Analysis
The trial was designed with a planned sample of 1000 study participants. This total allowed an estimated 20% dropout rate, leaving 800 participants. To reach the statistical power to detect a 0.2-SD difference in bone mineral content or bone crosssectional area, the estimate was 210 and 297 pQCT scans, respectively, in each group. 21 For infections, assuming an average annual infection rate of 6 for a child younger than 2 years, we estimated that detection of a decrease from 12 to 9 infections during the 24-month study period required a sample size of 220 per group to achieve a statistical power of 90%. 22, 23 Comparisons of baseline and follow-up characteristics and of biochemical measures were analyzed with the 2-tailed independent sample unpaired t test, Mann-Whitney test, or Pearson χ 2 as applicable. Logarithmic transformation was used for variables with nonnormal distribution. We assessed differences in bone strength between groups with a multivariate analysis of covariance. We used a crude model and an adjusted model, the latter using as covariates sex, age, weight, and quality of scans. Analyses were performed with IBM SPSS, version 22 (IBM).
To evaluate the effect of group on infection outcome measures, we applied a negative binomial model. Incidence was estimated as the proportion of follow-up time in personmonths, which allowed use of all available infection data, including data from incomplete study diaries. A complementary log-logistic model served to model the probability of at least 1 infection episode.
For group-season interaction analyses of infections, data were split into 1-month intervals. Random-effects models served for estimation to account for dependence of individual data on separate intervals (range, 3-25 months per participant). Analyses were performed with Stata statistical software, version 14 (StataCorp).
In the analyses, we applied the intention-to-treat principle. Per-protocol analyses included participants with treatment adherence of at least 80%. Two-sided P < .05 was considered statistically significant.
Results
Baseline Characteristics
Of the 4980 participants screened, 987 were found eligible and consented to participate. Twelve infants were excluded after randomization for not meeting eligibility criteria, leaving 975 infants, of whom 489 were randomly assigned to the 400-IU group and 486 to the 1200-IU group (Figure 1) . Of the 975 infants who were randomized, 485 (49.7%) were girls and all were of Northern European ethnicity. Baseline characteristics between groups did not differ ( Table 1) .
Adherence to Treatment
A total of 823 children (84.4%) completed the 24-month study; 865 (88.7%) attended the 12-month and 892 (91.5%) the 6-month follow-up (eTable 1 in Supplement 2). The cumulative number of participants lost to follow-up was 83 at 6 months, 110 at 12 months, and 152 at 24 months and did not differ between groups. The mean adherence to vitamin D supplementation during 24 months was 88% and was similar in both groups (eTable 2 in Supplement 2). At age 24 months, the proportion of children with at least 80% adherence was 83.5% (eTable 2 in Supplement 2).
Biochemical Effects
Mean (SD) 25(OH)D concentration at birth was 32.73 (11.14) ng/mL in the 400-IU group and 32.57 (9.62) ng/mL in the 1200-IU group; at 12 months, mean concentration was 33.13 (7.93) ng/mL in the 400-IU group and 46.07 (11.10) ng/mL in the 1200-IU group; and at 24 months, 34.70 (7.85) ng/mL in the 400-IU group and 47. 16 (10.46) Mean ionized calcium concentrations did not differ between groups (Figure 2 and eTable 3 in Supplement 2). At age 12 months, the ionized calcium concentrations were within age-specific reference limits in 838 (98.1%) of the 854 children evaluated, and at age 24 months concentrations were within age-specific limits in 667 (91.9%) of the 726 children evaluated (eTable 5 in Supplement 2). No participants developed severe hypercalcemia. At ages 12 and 24 months, the serum parathyroid hormone level was lower in the 1200-IU group than in the 400-IU group (Figure 2 and eTable 3 in Supplement 2). A per-protocol analysis was applied to all biochemical effects with consistent results.
Primary Outcomes
We performed pQCT bone scans of the left tibia in 783 of the 823 children (95.1%) attending the age 24-month follow-up. Owing to motion artifacts, 79 (10.1%) of the scans failed and were excluded. A total of 704 scans (89.9%) were included in the analyses. Of these, scan quality was assessed as good in 165 (48.1%) of the 400-IU group and 193 (53.5%) of the 1200-IU group participants, moderate in 124 (36.2%) of the 400-IU group and 133 (36.8%) of the 1200-IU group, and poor in 54 (15.7%) of the 400-IU group and 35 (9.7%) of the 1200-IU group. Bone strength measurements for total bone and cortical bone did not differ between groups ( Table 2 ). The findings remained unaltered in per-protocol analysis and after adjustment for sex, age, weight, and quality of scans.
Infection data from study diaries were obtained from 449 participants in the 400-IU group and 448 in the 1200-IU group; for 78 participants, data were completely missing. At the trial's end, 8458 parent-reported infection episodes had occurred, amounting to a mean 9.18 (95% CI, 8.73-9.63) in the 400-IU group and 9.14 (95% CI, 8.68-9.60) in the 1200-IU group, with no differences in incidence rates of infection between groups (incidence rate ratio [IRR], 1.00; 95% CI, 0.93-1.06); (Table 3 and eTable 6 in Supplement 2). Infection characteristics were similar; the majority were respiratory infections (eTable 7 in Supplement 2). The only difference between groups was a higher incidence rate of antibiotic treatment in the 1200-IU group (IRR 1.17; 95% CI, 1.00-1.36). Results did not change in per-protocol analysis or after adjustment for potential confounding factors (ie, parental educational level, existence of older siblings, parental smoking, day care attendance, season of birth, or duration of breastfeeding).
In interaction analyses, the only differences were for infection duration, indicating that, in winter and spring, duration was shorter in the 1200-IU group (test for 2 interactions: P = .01; winter: IRR, 0.89; 95% CI, 0.81-0.97; spring: IRR, 0.89; 95% CI, 0.81-0.99), and the likelihood of contracting gastroenteritis in winter was also lower in the 1200-IU group (test for interaction: P = .04; IRR, 0.76; 95% CI, 0.60-0.97).
Discussion
This study involving 975 healthy children is, to our knowledge, the first large randomized clinical trial evaluating vitamin D supplementation from infancy to early childhood. We observed no differences in bone strength measurements or in incidence of parent-reported infections between the 400-IU and 1200-IU intervention groups. Our study had adequate power to detect or exclude any but small differences between groups. At birth, 914 of 955 (95.7%) of the infants were vitamin D sufficient (had a 25[OH]D concentration ≥20.03 ng/mL), reflecting adequate maternal vitamin D intake. 24 At age 24 months, 809 of 814 (99.4%) of the study participants were vitamin D sufficient. None had a 25(OH)D concentration greater than 100.16 ng/mL or severe hypercalcemia, which are indicators of vitamin D toxicity. 5 These findings imply that a daily dose of 1200 IU of vitamin D 3 in this age group is safe, but even 400 IU will maintain vitamin D sufficiency in most children. We found no significant differences between the groups in any of the bone strength measurements, in line with randomized trials involving older vitamin D-sufficient children (aged 8-17 years) in which vitamin D dosages ranging from 132 IU/d to 14 000 IU/wk did not improve bone strength as measured by dual-energy x-ray absorptiometry or pQCT.
25 However, in an earlier study in 3-month-old infants, those with higher-dose vitamin D supplementation (1600 IU vs 400 IU) had larger tibial bone area compared with those receiving the lower dose. 26 The divergent results in the present study may result from this study's longer duration and larger cohort. In vitamin D-sufficient children, factors other than 25(OH)D concentration, such as motor competence, lean mass, or calcium intake, may have a greater influence on bone strength. 21, 27, 28 We observed no differences in the incidence of parentreported infections between the groups, with identical results in the per-protocol analyses. One recent large meta-analysis 13 In interaction analyses, however, we did observe the duration of infections in winter and spring in the 1200-IU group to be shorter than in the 400-IU group. This finding suggests that higher dosages of vitamin D may shorten the duration of illness during winter months, when infections are more frequent and when cutaneous synthesis of vitamin D is limited. However, this difference was marginal, was based on a post hoc analysis, and demands confirmation in future studies.
We hypothesized that higher dosages of vitamin D supplementation improve bone strength and reduce infections in early childhood in a northern European population with limited sunlight exposure. We expected a greater proportion of children to be vitamin D deficient at birth because studies conducted in 2007 
Limitations
The quality of bone scans varied, and movement artifacts were common owing to technical challenges in pQCT measurement in young children. However, 615 of the 704 scans (87.4%) were of good or moderate quality, with no differences between groups. We adjusted the statistical model by scan quality, with consistent results. On the other hand, pQCT gives more e Total number of days of illness during the 24-month follow-up.
f Duration of illness in days per infection episode.
Research Original Investigation
gard its use, instead of dual-energy x-ray absorptiometry, as a significant strength of our study. Assessment of infections was based on parents' report without clinical evaluation or laboratory confirmation, which may have led to underestimation or overestimation of infection prevalence. Definitions of infection may also vary. However, because the study was doubleblinded and controlled, any recall and observation bias is likely to be equally distributed between groups, although such bias could increase random error and thus reduce the likelihood of detecting differences. That the frequency and seasonal distribution of infections in our cohort corresponds to earlier findings in a similar age group further supports the validity of our data.
33,34
Conclusions
In vitamin D-sufficient healthy infants, daily supplementation with 1200 IU vitamin D 3 compared with 400 IU provides no additional benefits for bone strength or for parentreported incidence of infections during the first 2 years of life.
In a country where sunlight exposure is limited but food fortification with vitamin D is common, supplementation with 400 IU of vitamin D 3 daily seems adequate to ensure vitamin D sufficiency in children younger than 2 years. further studies are essential. 10, 11 In addition to its skeletal effects, vitamin D modulates both the innate and adaptive immune systems.
Immune cells express vitamin D receptor (VDR) and have local enzymatic capacity to synthetise active 1,25-dihydroxyvitamin D. 12, 13 Vitamin D induces production of antimicrobial peptides, such as cathelicidin, by monocytes and macrophages, and is involved in regulation of T-lymphocyte function. 14 In epidemiological studies, vitamin D deficiency has been associated with increased risk of infections both in adults and children. 15, 16 Results from randomised trials are inconclusive. For example, in Japan, a daily supplemental vitamin D3 dose of 30 g (1200 IU) for 4 months resulted in a significant reduction of influenza A infections, and in Mongolia, daily 7.5 g (300 IU) of vitamin D3 reduced the risk of acute respiratory infections in schoolchildren. 17, 18 However, in Afghan infants, the incidence of pneumonia was not affected by 18 months of vitamin D supplementation. 19 Further studies are needed to determine whether vitamin D supplementation provides benefits against infections in healthy children.
Primary outcomes
Primary outcomes of the study are bone strength measured by peripheral quantitative computed tomography (pQCT) and incidence of parent-reported infections at age 2 years.
Participants and methods
A total of 1 000 families are recruited and informed consent is obtained 1-2 days after the delivery at 
Follow-up
Participants are assessed at a study outpatient clinic by a study nurse and/or pediatrician at 6 months, 1 year and 2 years of age. Growth parameters (length, weight, head circumference) are measured and compared with Finnish growth charts. 20 Blood samples are taken for biochemistry. Bone strength of participants is evaluated by pQCT at 1 and 2 years of age. Families are provided study diaries where they keep daily records on dosing of vitamin D3 supplement and on all infections of the participating child. Nutrient intake from food is evaluated from 3-day food record at 1 year and a Food Frequency Questionnaire (FFQ) at 2 years of age. 
Specific methods
Biochemical markers
Bone strength
Bone strength is measured by pQCT from the distal left tibia using a XCT-2000 scanner (Stratec Medizintechnik GmbH, Pforzheim, Germany).
Infections
Data on infections are collected prospectively from daily diaries kept by parents of participating infants. Parents record the time and duration of the infection, symptoms, required medication, physician visit or hospitalisation in the daily diaries. Every 3-6 months, new diaries are provided to the families by mail or at follow-up visits, and completed diaries are returned to the study nurse.
Dietary vitamin D intake
At recruitment, maternal diet is evaluated retrospectively with a semi quantitative 22-item Food Frequency Questionnaire, for the time-period of one month before delivery.
At age 1 years, data on nutrient intake from food is collected with a three-day food record and analysed using AivoDiet software (Aivo Oy Finland, Turku, Finland). At 2 years, the dietary habits of the child are collected with 47-item Food Frequency Questionnaire. If the child attends daycare, the personnel are asked to complete a separate two-day food record.
Ethical issues and research permits
A recent intervention study confirmed the safety of vitamin D supplementation in infants with a daily dose of 50 g (2000 IU) daily. 21 Furthermore, we conducted a pilot study in 113 healthy newborns in order to evaluate short-term effects and safety of 3 different vitamin D3 doses (10 g, 30 g, 40 g daily). 22 No adverse events occurred and all doses were deemed safe. Based on the results, we chose daily doses of 10 g and 30 g for the intervention study.
An external clinical research institute monitors the study and possible adverse effects. As a safety protocol, the infants are monitored for hypercalcemia at follow-up visits. If the calcium concentration Blood samples are taken as follows: A) 20 ml from the umbilical vein after cord clamping at birth, B)
15 ml at age 1 year, and C) 20 ml at age 2 years. These volumes are clearly below the allowed maximal volumes for research sampling (approximate limits for research purposes are for ages 1 year:
24 ml and 2 years: 36 ml; i.e. 3% of circulating blood volume).
The radiation exposure from pQCT measurements is estimated to be 30 Sv, and exposure from whole-body DXA 50 Sv. This total dose of approximately 80 Sv equals radiation exposure during an overseas flight or 2 weeks' background radiation, and can thus be regarded as insignificant. 23 Similar methods have previously been used to study bone variables in newborns. 22 The vitamin D3 supplements are provided by Orion Pharmaceuticals free of charge. The study is researcher initiated and independent. 
STATISTICAL ANALYSIS PLAN Sample size calculation and statistical analyses
We aim at detecting a 0.2 SD unit difference between continuous bone strength parameters; bone mineral content and cross-sectional area. In order to reach a statistical power of 90% with significance level of 0.05, a total of 210 and 297 measurements, respectively, are necessary. 1 In addition, challenges in measuring infants with pQCT may occur. According to previous studies, small children suffer from an average of 6 infections annually. 2, 3 In order to detect a decrease from 12 to 9 infections during the 24-month study period, a sample size of 220 in each group is required. We estimate a possible drop-out rate of 20%. Taking into consideration all the aforementioned aspects, the trial is designed for 1000 subjects: 500 subjects in each intervention group.
Statistical methods
Comparisons between two intervention groups are analysed with independent samples t-test, Mann 
Family background data
We collected family demographics, including data on health and lifestyle factors, with self-administered research questionnaires at recruitment. Data on gestation and delivery, and on infant demographics, came from electronic hospital records. Season of birth was categorized as in winter (December, January, February), spring (March, April, May), summer (June, July, August) or autumn (September, October, November).
Maternal body mass index (BMI, kg/m 2 ) was calculated from weight and height measured before pregnancy. We collected data on maternal use of vitamin D supplements (brand name, dosage, and date of commencement), and calculated average daily vitamin D intake from supplements for the last 2 months of pregnancy. Parents' educational level from the questionnaires was graded from 1 (=comprehensive school) to 6 (university degree) and then recategorized into 2 levels: low educational level (=less than a bachelor's degree) and high educational level (=at least a bachelor's degree). Data also included parental smoking before pregnancy and after the delivery.
At the 24-month follow-up, we collected data with structured questionnaires on family lifestyle factors, child's daycare attendance, and household annual income using structured questionnaires. Household annual income was graded into 9 categories: 0-12,999 euro, 13,000-19,999, 20,000-39,999, 40,000-59,999, 60,000-89,000, 90,000-109,999, 110,000-139,999, 140,000 or above, and unknown and further re-categorized into low income (below 40,000), medium income (40,000-109,999), and high income (110,000 and above).
Nutritional data
Dietary intakes of vitamin D and calcium were determined at 12 months from a 3-day food record administered by the parents or daycare personnel. Families were instructed to record all foods and beverages consumed by the child with the amounts and detailed description of the food item, as well as breastfeeding. Amounts of each food item were estimated by household measurements or by weighing on a scale. Completed food records were reviewed by a nutritionist, and nutrient intakes were processed with AivoDiet software (Aivo Oy Finland, Turku, Finland), which utilizes Fineli, the National Food Composition Database maintained by Finland's National Institute for Health and Welfare. The volume of breast milk consumed was unknown, meaning that calculated total vitamin D and calcium intakes included no intake from breast milk.
Duration of breastfeeding came from repeated questionnaires incorporated in to the study diaries. For mothers still breastfeeding at the 24-month follow-up, the duration of breastfeeding was recorded as 24 months.
Anthropometric measurements
Follow-up visits were arranged at the study clinic at Kätilöopisto Helsinki Maternity Hospital, Finland, at the child's 6 th , 12 th , and 24 th month of age (+/-1 month). At each follow-up visit, the child was measured for weight (kg) with a scale (Seca®, Hamburg, Germany) and for length (cm) with a table-top meter. Length at follow-up was expressed as standard deviation score (SDS) and weight as length-adjusted weight using age-and sex-specific Finnish reference values. Group400 represents infants randomized to daily 400 IU vitamin D3 and Group1200 to daily 1200 IU vitamin D3. All values are means with standard deviation (SD). SDS denotes standard deviation score. Data on weight and length at 12 months available for 864; data on weight at 24 months for 820, and data on length at 24 months for 821.
All
Group 400 Group 1200
6-month follow-up
Number of subjects 892 447 445
Weight ( 
